Clinical Trial Update: To Demonstrate the Superiority of IMP (0.3% and 1% OPA-15406 Ointment) Versus the Vehicle in Pediatric Patients with AD [Phase 3]

View source ↗

Summary

A Phase 3 pediatric trial evaluating whether OPA-15406 ointment at 0.3% and 1% is superior to vehicle in treating Atopic Dermatitis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atopic Dermatitis

Drugs mentioned

• OPA-15406 ointment (OPA-15406)

Snippet

Sponsor: Otsuka Beijing Research Institute | Conditions: Atopic Dermatitis (AD) | Phase 3 | Status: COMPLETED